Pharvaris N.V. (PHVS)

Pharvaris N.V. (PHVS) Healthcare & Pipeline Overview

Pharvaris N.V. is a clinical-stage biopharmaceutical company specializing in rare disease therapies, primarily targeting hereditary angioedema (HAE). Their pipeline features novel, small-molecule bradykinin B2-receptor antagonists, positioning them as an emerging player in the competitive biotechnology landscape with a focus on unmet medical needs.

What Is the Investment Thesis for PHVS?

Pharvaris N.V. presents a notable research candidate within the rare disease therapeutics market, specifically targeting hereditary angioedema (HAE). The company's focus on developing novel, small-molecule bradykinin B2-receptor antagonists addresses a significant unmet medical need. Positive Phase II clinical trial results for PHA121 could serve as a major catalyst, driving stock appreciation. Successful advancement of PHVS416 and PHVS719 through clinical trials would further de-risk the pipeline and expand the company's market potential. However, the negative beta of -2.58 indicates high volatility. The company's success hinges on favorable clinical trial outcomes and regulatory approvals. With a market cap of $2.33B, Pharvaris offers substantial growth potential if its clinical programs are successful.

Based on FMP financials and quantitative analysis

PHVS Key Highlights

• Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases, particularly hereditary angioedema (HAE).
• The company's lead product candidate, PHA121, is a small molecule bradykinin B2-receptor antagonist in Phase II clinical trial for HAE treatment.
• PHVS416, an on-demand, rapid exposure soft capsule for acute HAE attacks, is in Phase 2 clinical trials.
• PHVS719, a prophylactic extended-release tablet for HAE patients, is in Phase 1 clinical trials.
• The company operates in the Netherlands, Switzerland, and the United States, indicating a global strategy.

Who Are PHVS's Competitors?

PHVS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHVS's Key Strengths?

• Novel bradykinin B2-receptor antagonist approach.
• Pipeline of product candidates in various clinical stages.
• Experienced management team.
• Focus on a specific rare disease with unmet needs.

What Are PHVS's Weaknesses?

• Clinical-stage company with no currently marketed products.
• Reliance on successful clinical trial outcomes.
• High cash burn rate.
• Negative beta indicates high volatility.

What Could Drive PHVS Stock Higher?

• Data readout from Phase II clinical trial of PHA121 in late 2026.
• Initiation of Phase III clinical trials for PHVS416 in 2027, pending Phase II results.
• Advancement of PHVS719 into Phase II clinical trials in 2027.
• Potential for strategic collaborations and partnerships to accelerate pipeline development.

What Are the Key Risks for PHVS?

• Negative return on equity (-67.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure to achieve positive results in clinical trials.
• Regulatory delays or rejection of marketing applications.
• Competition from established and emerging HAE therapies.
• Dependence on securing additional funding to support clinical development.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for PHVS?

• Growth opportunity 1: Successful completion of Phase II clinical trials for PHA121 represents a significant growth opportunity. Positive results could lead to accelerated regulatory pathways and potential commercialization, addressing a substantial unmet need in the HAE market. The market for HAE therapies is projected to reach several billion dollars by 2030, offering Pharvaris a substantial revenue opportunity if PHA121 proves effective and safe. Timeline: Anticipated Phase II data readout in late 2026.
• Growth opportunity 2: The development and commercialization of PHVS416, an on-demand treatment for acute HAE attacks, presents another key growth driver. This rapid-exposure soft capsule aims to provide patients with a convenient and effective solution for managing acute episodes. The acute HAE treatment market is a significant segment within the overall HAE market, and PHVS416 could capture a substantial share if it demonstrates superior efficacy and convenience compared to existing therapies. Timeline: Potential Phase III initiation in 2027.
• Growth opportunity 3: The advancement of PHVS719, a prophylactic extended-release tablet for HAE patients, offers a long-term growth opportunity. Prophylactic treatments aim to reduce the frequency and severity of HAE attacks, improving patients' quality of life. The prophylactic HAE treatment market is a growing segment, driven by the desire for long-term disease management. If PHVS719 demonstrates sustained efficacy and safety, it could become a preferred option for HAE patients seeking proactive disease control. Timeline: Potential market launch in 2029, pending successful clinical trials and regulatory approval.
• Growth opportunity 4: Expansion into new geographic markets represents a strategic growth opportunity for Pharvaris. While the company currently operates in the Netherlands, Switzerland, and the United States, expanding into other regions with significant HAE patient populations could drive revenue growth. This expansion could involve establishing partnerships with local distributors or establishing a direct commercial presence. The global HAE market is largely untapped, offering Pharvaris significant potential for geographic expansion. Timeline: Ongoing, with potential for expansion into new markets in 2027-2030.
• Growth opportunity 5: Strategic collaborations and partnerships with other pharmaceutical companies or research institutions could accelerate the development and commercialization of Pharvaris's pipeline. Collaborations could provide access to additional funding, expertise, and resources, enhancing the company's ability to bring its therapies to market. These partnerships could also involve licensing agreements or joint ventures, expanding the company's product portfolio and market reach. Timeline: Ongoing, with potential for new partnerships to be announced in 2026-2028.

What Opportunities Does PHVS Have?

• Positive clinical trial results for lead product candidates.
• Regulatory approval and commercialization of HAE therapies.
• Expansion into new geographic markets.
• Strategic collaborations and partnerships.

What Threats Does PHVS Face?

• Failure of clinical trials.
• Regulatory delays or rejection.
• Competition from existing and emerging HAE therapies.
• Patent challenges.

What Are PHVS's Competitive Advantages?

• Proprietary small molecule bradykinin B2-receptor antagonists.
• Patent protection for its lead product candidates.
• Clinical data demonstrating efficacy and safety.
• Focus on a specific rare disease (HAE) with unmet needs.

What Does PHVS Do?

Pharvaris N.V., incorporated in 2015 and based in Leiden, the Netherlands, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases. The company's primary focus is on hereditary angioedema (HAE), a genetic disorder characterized by recurrent episodes of severe swelling. Pharvaris is pioneering the development of novel, small-molecule bradykinin B2-receptor antagonists to address the unmet needs of HAE patients. Their lead product candidates include PHA121, an oral bradykinin B2-receptor antagonist currently in Phase II clinical trials for HAE treatment. Additionally, the company is developing PHVS416, an on-demand, rapid-exposure soft capsule designed for acute HAE attacks, which is also in Phase 2 clinical trials. PHVS719, a prophylactic extended-release tablet for HAE patients, is in Phase 1 clinical trials. Pharvaris operates across the Netherlands, Switzerland, and the United States, reflecting its global ambitions in the rare disease therapeutics market. The company aims to provide HAE patients with effective and convenient treatment options, improving their quality of life and reducing the burden of this debilitating condition. By focusing on bradykinin B2-receptor antagonism, Pharvaris is pursuing a targeted approach to address the underlying pathophysiology of HAE, potentially offering significant advantages over existing therapies.

What Products and Services Does PHVS Offer?

• Develop small molecule bradykinin B2-receptor antagonists.
• Focus on therapies for rare diseases.
• Target hereditary angioedema (HAE) with novel treatments.
• Conduct Phase II clinical trials for PHA121.
• Develop on-demand treatments for acute HAE attacks (PHVS416).
• Develop prophylactic extended-release tablets for HAE patients (PHVS719).

How Does PHVS Make Money?

• Develop and patent novel pharmaceutical products.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA and EMA.
• Commercialize approved therapies through direct sales or partnerships.

What Industry Does PHVS Operate In?

The biotechnology industry is characterized by high innovation and significant investment in research and development. The rare disease therapeutics market, in particular, is experiencing substantial growth due to increasing awareness, regulatory incentives, and unmet medical needs. Pharvaris N.V. operates within this dynamic landscape, focusing on hereditary angioedema (HAE), a rare genetic disorder. The competitive landscape includes companies developing alternative HAE therapies, but Pharvaris's focus on bradykinin B2-receptor antagonism offers a differentiated approach. The company's success depends on its ability to navigate the complex regulatory environment and demonstrate clinical efficacy.

Who Are PHVS's Key Customers?

• Patients suffering from hereditary angioedema (HAE).
• Physicians specializing in the treatment of HAE.
• Hospitals and clinics that treat HAE patients.
• Pharmacies that dispense HAE medications.

How Pharvaris N.V. Is Valued

Pharvaris N.V. carries a market capitalization of $2.33B, placing it in the mid-cap category. Relative to its peer group, PHVS's quantitative score of 51/100 is below the peer average of 78/100.

Company Profile

Pharvaris N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Leiden, NL. The company is led by CEO Berndt Modig. PHVS has traded publicly since 2021.

ROE -67%Key Financial Metrics

Return on equity for Pharvaris N.V. stands at -67.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 11.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Pharvaris N.V.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 48.53 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Pharvaris N.V. revenue of about $1.3M for fiscal 2026, with EPS near $-2.59. The estimate reflects 9 contributing analysts.

PHVS Financials

PHVS Latest News

PHVS Analyst Consensus

PHVS MoonshotScore

Pharvaris N.V. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources